Long-term oral vitamin E supplementation in cystic fibrosis patients: RRR-α-tocopherol compared with all-rac-α-tocopheryl acetate preparations

American Journal of Clinical Nutrition

Volumn 63, Issue 5, 1996, Pages 722-728

  Winklhofer Roob, Brigitte M ^a   Van't Hof, Martin A ^b   Shmerling, David H ^b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b NONE

Author keywords

All rac tocopheryl acetate; Cystic fibrosis; Liver disease; Long term supplementation; RRR tocopherol; Water miscible vitamin E

Indexed keywords

ALPHA TOCOPHEROL;

ADOLESCENT; ADULT; ALPHA TOCOPHEROL DEFICIENCY; ARTICLE; CHILD; CLINICAL ARTICLE; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SCREENING; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; VITAMIN BLOOD LEVEL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ALPHA-TOCOPHEROL; ANTIOXIDANTS; CHILD; CHILD, PRESCHOOL; CHOLESTEROL; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT; LIVER DISEASES; MALE; TIME FACTORS; VITAMIN E; VITAMIN E DEFICIENCY;

EID: 0029918804     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/63.5.722     Document Type: Review

References (47)

1. Gaskin K, Gurwitz D, Durie P, Corey P, Levison H, Forstner G. Improved respiratory prognosis in patients with cystic fibrosis with normal fat absorption. J Pediatr 1982;100:857-62.
2. Farrell PM, Bieri IG, Fratantoni JF, Wood RE, Di Sant'Agnese PA. The occurrence and effects of human vitamin E deficiency. A study in patients with cystic fibrosis J Clin Invest 1977;60:233-41.
3. Stead RJ, Muller DPR, Matthews S, Hodson ME, Batten JC. Effect of abnormal liver function on vitamin E status and supplementation in adults with cystic fibrosis. Gut 1986;27:714-8.
4. Congden PJ, Bruce G, Rothburn MM, et al. Vitamin status in treated patients with cystic fibrosis. Arch Dis Child 1981;56:708-14.
5. Ramsey BW, Farrell PM, Pencharz P, and the Consensus Committee. Nutritional assessment and management in cystic fibrosis: a consensus report. Am J Clin Nutr 1992;55:108-16.
6. Peters SA, Rolles CJ. Vitamin therapy in cystic fibrosis - a review and rationale. J Clin Pharm Ther 1993;18:33-8.
7. Winklhofer-Roob BM, Shmerling DH, Schimek MG, Tuchschmid PE. Short-term changes in erythrocyte α-tocopherol content of vitamin E-deficient patients with cystic fibrosis. Am J Clin Nutr 1992;55: 100-3.
8. Winklhofer-Roob BM, Tuchschmid PE, Molinari L, Shmerling DH. Response to a single oral dose of all-rac-α-tocopheryl acetate in patients with cystic fibrosis and in healthy individuals. Am J Clin Nutr 1996;63:517-21.
9. Sokol RJ, Reardon MC, Accurso FJ, et al. Fat-soluble-vitamin status during the first year of life in infants with cystic fibrosis identified by screening of newborns. Am J Clin Nutr 1989;50:1064-71.
10. Sokol RJ, Erskine J, Abman S, Wagener J, Hammond K, Accurso F. Prospective study of fat-soluble vitamin status in 101 infants with cystic fibrosis identified by newborn screening. Pediatr Pulmonol 1993;16(suppl 9):278(abstr).
11. Kelleher J, Miller MG, Littlewood JM, McDonald AM, Losowsky MS The clinical effect of correction of vitamin E depletion in cystic fibrosis. Int J Vitam Nutr Res 1987;57:253-9.
12. Harries JT, Muller DPR. Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Arch Dis Child 1971;46:341-4.
13. Nasr SZ, O'Leary MH, Hillermeier C. Correction of vitamin E deficiency with fat-soluble versus water-miscible preparations of vitamin E in patients with cystic fibrosis. J Pediatr 1993;122:810-2.
14. Parfitt VJ, Rubba P, Bolton C, Marotta G, Hartog M, Mancini M. A comparison of antioxidant status and free radical peroxidation of plasma lipoproteins in healthy young persons from Naples and Bristol. Eur Heart J 1994;15:871-6.
15. Dieber-Rotheneder M, Puhl H, Waeg G, Striegl G, Esterbauer H. Effect of oral supplementation with D-α-tocopherol on the vitamin E content of human low density lipoproteins and resistance to oxidation. J Lipid Res 1991;32:1325-32.
16. Winklhofer-Roob BM, Ziouzenkova O, Puhl H, et al. Impaired resistance to oxidation of low density lipoprotein in cystic fibrosis. Improvement during vitamin E supplementation. Free Radic Biol Med 1995;19:725-33.
17. Packer L. Vitamin E. Biological activity and health benefits: overview. In: Packer L, Fuchs J, eds. Vitamin E in health and disease. New York: M Dekker, 1993:977-82.
18. Byers T, Perry G. Dietary carotenes, vitamin C, and vitamin E as protective antioxidants in human cancers. Annu Rev Nutr 1992;12: 139-59.
19. Meydani SN, Barklund MP, Liu S, et al. Vitamin E supplementation enhances cell-mediated immunity in healthy elderly subjects. Am J Clin Nutr 1990;52:557-63.
20. Gey KF, Stähelin HB, Puska P, Evans A. Relationship of plasma level of vitamin C to mortality from ischemic heart disease. Ann N Y Acad Sci 1987;498:110-23.
21. Winklhofer-Roob BM. Oxygen free radicals and antioxidants in cystic fibrosis. The concept of an oxidant-antioxidant imbalance. Acta Paediatr 1994;83(suppl 395):49-57.
22. Brown RK, Kelly FJ. Evidence for increased oxidative damage in patients with cystic fibrosis. Pediatr Res 1994;36:487-93.
23. Winklhofer-Roob BM, Schlegel-Haueter SE, Khoschsorur G, Suter S, Shmerling DH. Serum neutrophil elastase/α1-antiprotease complexes and lipid peroxides decrease during improvement of vitamin E and β-carotene status in cystic fibrosis. FASEB J 1995;9: A854(abstr).
24. McKenna MC, Hubbard VS, Bieri JG. Linoleic acid absorption from lipid supplements in patients with cystic fibrosis with pancreatic insufficiency and in control subjects. J Pediatr Gastroenterol Nutr 1985; 4:45-51.
25. Mischler EH, Parrell SW, Farrell PM, Raynor WJ, Lemen RJ. Correction of linoleic acid deficiency in cystic fibrosis. Pediatr Res 1986; 20:36-41.
26. Henderson WR Jr, Astley SJ, McCready MM, et al. Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects. J Pediatr 1994;124: 400-8.
27. Christophe A, Robberecht E, Franckx H, De Baets F, van de Pas M. Effect of administration of gamma-linolenic acid on the fatty acid composition of serum phospholipids and cholesteryl esters in patients with cystic fibrosis. Ann Nutr Metab 1994;38:40-7.
28. Shmerling DH, Forrer JCW, Prader A. Fecal fat and nitrogen in healthy children and in children with malabsorption or maldigestion. Pediatrics 1970;46:690-5.
29. Vuilleumier JP, Keller HE, Gysel D, Hunziker F. Clinical chemical methods for the routine assessment of the vitamin status in human populations. Part I: The fat-soluble vitamins A and E, and β-carotene. Int J Vitam Nutr Res 1983;53:265-72.
30. Thurnham DI, Davies JA, Crump BJ, Situnayake RD, Davis M. The use of different lipids to express serum tocopherol:lipid ratios for the measurement of vitamin E status. Ann Clin Biochem 1986;23: 514-20.
31. James DR, Alfaham M, Goodchild MC. Increased susceptibility to peroxide-induced haemolysis with normal vitamin E concentrations in cystic fibrosis. Clin Chim Acta 1991;204:279-90.
32. Dimitrov NV, Meyer C, Gilliland D, Ruppenthal M, Chenoweth W, Malone W. Plasma tocopherol concentrations in response to supplemental vitamin E. Am J Clin Nutr 1991;53:723-9.
33. Baker H, Handelman GJ, Short S, et al. Comparison of piasma α and γ tocopherol levels following chronic oral administration of either all-rac-α-tocopheryl acetate or RRR-α-tocopheryl acetate in normal adult male subjects. Am J Clin Nutr 1986;43:382-7.
34. Brin MF, Fahn S, Loftus S, McMahon D, Flaster E. Relationship between dose of vitamin E administered and blood level. Ann N Y Acad Sci 1989;570:421-4.
35. Winklhofer-Roob BM, Ziouzenkova O, Gollner K, et al. Effect of oral vitamin E supplementation on lipid peroxidation in cystic fibrosis (CF). Pediatr Pulmonol 1994;18(suppl 10):281(abstr).
36. Weiser H, Vecchi M. Stereoisomers of α-tocopheryl acetate. II. Biopotencies of all eight stereoisomers, individually or in mixtures, as determined by rat resorption-gestation tests. Int J Vitam Nutr Res 1982;52:351-70.
37. Ferslew KE, Acuff RV, Daigneault EA, Woolley TW, Stanton PE Jr. Pharmacokinetics and bioavailability of the RRR and all racemic stereoisomers of alpha-tocopherol in humans after single oral administration. J Clin Pharmacol 1993;33:84-8.
38. Horwitt MK, Elliott WH, Kanjananggulpan P, Fitch CD. Serum concentrations of α-tocopherol after ingestion of various vitamin E preparations. Am J Clin Nutr 1984;40:240-5.
39. Traber MG, Burton GW, Ingold KU, Kayden HJ. RRR- and SRR-α-tocopherols are secreted without discrimination in human chylomicrons, but RRR-α-tocopherol is preferentially secreted in very low density lipoproteins. J Lipid Res 1990;31:675-85.
40. Traber MG, Sokol RJ, Kohlschütter A, et al. Impaired discrimination between stereoisomers of α-tocopherol in patients with familial isolated vitamin E deficiency. J Lipid Res 1993;34:201-10.
41. Ouahchi K, Arita M, Kayden H, et al. Ataxia with isolated vitamin E deficiency is caused by mutations in the α-tocopherol transfer protein. Nature Genet 1995;9:141-5.
42. Traber MG, Ramakrishnan R, Kayden HJ. Human plasma vitamin E kinetics demonstrate rapid recycling of plasma RRR-α-tocopherol. Proc Natl Acad Sci USA 1994;91:10005-8.
43. Acuff RV, Thedford SS, Hidiroglou NN, Papas AM, Odom TA Jr. Relative bioavailability of RRR- and all-rac-α-cocopheryl acetate in humans: studies using deuterated compounds. Am J Clin Nutr 1994; 60:397-402.
44. Kelleher J, Losowsky MS. The absorption of α-tocopherol in man. Br J Nutr 1970;24:1033-47.
45. Mathias PM, Harries JT, Peters TJ, Muller DPR. Studies on the in vivo absorption of micellar solutions of tocopherol and tocopheryl acetate in the rat: demonstration and partial characterization of a mucosal esterase localized to the endoplasmic reticulum of the enterocyte. J Lipid Res 1981;22:829-37.
46. Burton GW, Ingold KU, Foster DO, et al. Comparison of free α-to-copherol and α-tocopheryl acetate as sources of vitamin E in rats and humans. Lipids 1988;23:834-40.
47. Kappus H, Diplock AT. Tolerance and safety of vitamin E: a toxicological position report. Free Radic Biol Med 1992;13:55-74.